SLC5A2 and hydrops fetalis: Significant advances can be achieved by using repurposed HF drugs (e.g., SGLT2 inhibitors), human pluripotent stem cell-derived cardiomyocytes, and therapeutic targets like microRNAs to understand the processes leading to DOX-induced cardiotoxicity.